At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
evinacumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
In Brief
A Phase 2 clinical trial evaluating evinacumab and Placebo for Severe Hypertriglyceridemia (sHTG). Completed, enrolled 52 participants across 17 sites in 4 countries.
Detailed Summary
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hypertriglyceridemia (sHTG)
CountriesCanada, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartJun 2018
Primary CompletionDec 2019
Study CompletionJul 2020
TodayJul 2026
First PostedMar 2, 2018
Enrollment StartJun 7, 2018
Primary CompletionDec 17, 2019
Study CompletionJul 23, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.3 years ago
Interventions
evinacumabdrug
Administered by Intravenous (IV)
Placebodrug
Administered by Intravenous (IV)